Abstract: In at least one embodiment, a display device includes: a correction section for carrying out gray scale correction on gray scale data to be supplied to a display driver, by use of a correction amount corresponding to a position of each column to which the data signal is to be supplied, the each column being on a display panel, the correction section carrying out the gray scale correction by setting the correction amount to zero for at least (i) gray scale data corresponding to a lowest positive-polarity data signal potential and (ii) gray scale data corresponding to a lowest negative-polarity data signal potential of first gray scale data to be supplied to at least one column constituting a part of all columns, the gray scale data (i) and (ii) being among the gray scale data inputted into the correction section.

Abstract: In an evaporator constituting part of a vehicular air conditioning apparatus, a first cooling section that faces a first front passage, and a second cooling section that faces a first rear passage are provided. At a boundary portion between the first cooling section and the second cooling section, a partition member constituted by a filled and hardened packing agent is formed. The partition member is formed so as to fill spaces, which are located between first fins that constitute the first cooling section and second fins that constitute the second cooling section. Air that flows through the first cooling section and air that flows through the second cooling section do not mix together in the interior of the evaporator by the partition member.

Abstract: A display device of at least one embodiment of the present invention includes at least one correcting device for, in a case where a first data signal is to be written to a first pixel during a unique horizontal period, (i) carrying out a first gray scale correction with respect to display data corresponding to the first data signal to be written to the first pixel during the unique horizontal period, and (ii) supplying the display data to a display driver, the unique horizontal period being a first horizontal period for one of the driving signals supplied to respective storage capacitor bus lines which first horizontal period occurs a first number of horizontal periods after an initial horizontal period included in a given cyclic term for either or both of a binary level, the given cyclic term being a second cyclic term for the driving signals which second cyclic term occurs a second number of cyclic terms after a first cyclic term including a horizontal period during which the data signals start to be writte

Abstract: Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

Abstract: The present invention provides compounds that are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.

Abstract: The present invention relates to an agent for suppressing STAT3 phosphorylation and for suppressing Notch1 expression comprising as an active ingredient a compound represented by the following formula (1): wherein R1, R2 and R3 each independently represents a hydrogen atom or a methyl group; and X represents a linear or branched alkyl, alkylene or alkenylene group having 10 to 28 carbon atoms.

Abstract: In a vehicular air conditioning apparatus, a first blower unit is connected by a connection duct to a side portion of a casing constituted by respective air passages, and a second blower unit separate from the first blower unit is connected to a Lower portion of the casing. The first blower unit adjusts an inflow rate of external air by means of an adjustment damper, which is disposed to face toward an opening of a duct, and the external air flows into the casing through an intake damper.

Abstract: A preventive and/or therapeutic agent for diabetes complications, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic derivative represented by the following formula (1): wherein, R1, R2 and R3 each independently represents a hydrogen atom or a methyl group and X represents a linear or branched C10-28 alkylene or alkenylene group. The cyclohexenone long-chain alcoholic derivative of the present invention significantly suppresses a reduction in a peripheral nerve conduction rate and alleviates the hypofunction of the bladder so that it is useful as a preventive and/or therapeutic agent for diabetes complications, particularly, for diabetic neuropathy.

Abstract: A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into the cells. The clay mineral is preferably a layered clay mineral, and as the clay mineral it is possible to use montmorillonite, vermiculite, and illite, for example.

Abstract: A vehicle door structure includes: a door body that includes an inner panel and an outer panel and that has a space between the inner panel and the outer panel; an acceleration detector that is arranged in the space; a support portion that supports the acceleration detector on the door body so that a direction of sensitivity of the acceleration detector differs from a direction in which the door body is closed; and a sensitivity direction changing portion that changes a position in which the acceleration detector is supported by the support portion so that the direction of sensitivity of the acceleration detector approaches a direction in which the inner panel faces the outer panel as the outer panel is relatively displaced toward the inner panel.

Abstract: The present invention relates to an agent for suppressing STATS phosphorylation and for suppressing Notch1 expression comprising as an active ingredient a compound represented by the following formula (1): wherein R1, R2 and R3 each independently represents a hydrogen atom or a methyl group; and X represents a linear or branched alkyl, alkylene or alkenylene group having 10 to 28 carbon atoms.

Abstract: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2?,5?-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40 to 98% by weight of acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and 1 to 30% by weight of saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 10 to 30.

Abstract: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and fatty acid ester prepared by dehydro-condensing saturated fatty acid having an alkyl group with a carbon number of 10 to 20 and saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 2 to 20, wherein solubility of the DMAEs is 0.05 to 5 g at 25° C. with respect to the fatty acid ester.

Abstract: The present invention provides therapeutic agents for sensory disorders represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.

Abstract: The present invention provides compounds represented by formula (1) shown below: (wherein R1, R2, R3, R4, and R5 are each individually selected from among a hydrogen atom, methyl group, acetyl group, hydroxyl group, and alkoxy group; and X represents an alkylene group or alkenylene group); and compounds represented by formula (2) shown below: (wherein R6, R7, R8, R9, and R10 are each individually selected from among a hydrogen atom, alkyl group, acetyl group, hydroxyl group, and alkoxy group; A represents an oxygen atom or NH, and m is 0 or 1; and Y represents an alkylene group or alkenylene group, and Z represents a hydrogen atom or hydroxyl group). The compounds of the present invention are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.

Abstract: The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. Since the cyclohexenone long chain alcohol of formula (1) improves diabetic vascular smooth muscle contraction and bronchial smooth muscle contraction, it is useful as a preventive and/or therapeutic agent for a diabetic vascular disorder or a respiratory disorder.

Abstract: Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

Abstract: Provided is an indole long-chain alcohol, or a hydrate or an isomer thereof, represented by the following formula (I): wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect, as well as potent antioxidative and anti-tumor effects, and is therefore useful as a prophylactic and/or therapeutic agent for cerebral diseases including dementia diseases, and malignant tumors including brain tumors.

Abstract: A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into the cells. The clay mineral is preferably a layered clay mineral, and as the clay mineral it is possible to use montmorillonite, vermiculite, and illite, for example.

Abstract: The objective of the present invention is to identify compounds having an inhibitory effect on adipocyte differentiation, and to provide pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases. By enthusiastically studying natural products that inhibit the differentiation induction of adipocyte precursors into adipocytes, sesquiterpenoid derivatives, which are extracts from a Compositae plant, Calea, growing in Central and South America, were demonstrated to have an excellent inhibitory effect on adipocyte differentiation induction. Calea extract or the sesquiterpenoid derivatives are expected to be used in pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases.